JP2024502170A5 - - Google Patents

Info

Publication number
JP2024502170A5
JP2024502170A5 JP2023541633A JP2023541633A JP2024502170A5 JP 2024502170 A5 JP2024502170 A5 JP 2024502170A5 JP 2023541633 A JP2023541633 A JP 2023541633A JP 2023541633 A JP2023541633 A JP 2023541633A JP 2024502170 A5 JP2024502170 A5 JP 2024502170A5
Authority
JP
Japan
Prior art keywords
cells
cell
tumor
cell composition
sak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502170A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2022/050038 external-priority patent/WO2022153295A1/en
Publication of JP2024502170A publication Critical patent/JP2024502170A/ja
Publication of JP2024502170A5 publication Critical patent/JP2024502170A5/ja
Pending legal-status Critical Current

Links

JP2023541633A 2021-01-12 2022-01-11 癌のための改良された養子細胞移植療法 Pending JP2024502170A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163136217P 2021-01-12 2021-01-12
US63/136,217 2021-01-12
PCT/IL2022/050038 WO2022153295A1 (en) 2021-01-12 2022-01-11 Improved adoptive cell transfer therapy for cancer

Publications (2)

Publication Number Publication Date
JP2024502170A JP2024502170A (ja) 2024-01-17
JP2024502170A5 true JP2024502170A5 (cg-RX-API-DMAC7.html) 2024-11-06

Family

ID=82447153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541633A Pending JP2024502170A (ja) 2021-01-12 2022-01-11 癌のための改良された養子細胞移植療法

Country Status (5)

Country Link
US (1) US20240307536A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277638A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502170A (cg-RX-API-DMAC7.html)
IL (1) IL304373A (cg-RX-API-DMAC7.html)
WO (1) WO2022153295A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121378506A (zh) * 2025-10-21 2026-01-23 北京京科信拓生物技术有限公司 表达car的免疫细胞及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090875B2 (en) * 2008-01-29 2015-07-28 Fred Hutchinson Cancer Research Center Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Nk細胞の増殖
WO2019106163A1 (en) * 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
US20240083973A1 (en) * 2019-10-09 2024-03-14 Ecole Normale Supérieure de Lyon T cells modified to express mutated cxcr4 or partially deleted and uses thereof
IL293350A (en) * 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
MX2022015586A (es) * 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.

Similar Documents

Publication Publication Date Title
JP7527049B2 (ja) Car発現ベクター及びcar発現t細胞
US20250109180A1 (en) Immunomodulatory fusion proteins and uses thereof
JP7696658B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
KR102483822B1 (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2022113880A (ja) 免疫調節性融合タンパク質およびその使用
JP6985934B2 (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
ES2995785T3 (en) Gene therapy
US20170313759A1 (en) Novel chimeric antigen receptors
JP2019536452A (ja) 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
KR20180012754A (ko) 변형된 감마 델타 t 세포 및 이의 용도
KR20140023931A (ko) 세포 면역요법용 방법 및 조성물
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
JP2022512450A (ja) Gpc3を標的とする免疫エフェクター細胞およびその応用
WO2022232277A1 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH
JP6842688B2 (ja) キメラ抗原受容体
US20240307536A1 (en) Improved adoptive cell transfer therapy for cancer
JP7054181B2 (ja) キメラ抗原受容体
Biondi Enhancing AML CAR CIK therapeutic potency increasing the localization of engineered cells in the malignant niche and its selectivity by LSCs specific targeting
WO2025224123A1 (en) Chimeric antigen receptors specific for fibroblast activation protein
Han Engineering Chimeric Antigen Receptor T Cells towards Enhanced Safety and Efficacy in Cancer Immunotherapy
HK1235426B (en) Car expression vector and car-expressing t cells